Delcath cancer drug delivery system aids survival

* Patients lived 245 days vs 49 days on standard care

* Further update due Saturday afternoon

CHICAGO, June 5 (BestGrowthStock) – A drug delivery system
developed by Delcath Systems Inc (DCTH.O: ) helped melanoma
patients whose cancer had spread to their liver live much
longer than patients treated with best available care.

The company, which announced in April that the 93-patient
trial was successful, will present the detailed results later
on Saturday at a meeting of the American Society of Clinical
Oncology in Chicago.

A preliminary summary provided to ASCO earlier showed that
patients treated with Delcath’s PHP System lived for an average
of 245 days before dying or having their cancer get worse.
Patients treated with standard drugs survived for an average of
49 days before they died or their tumor growth restarted.

Delcath’s system is designed to deliver high doses of the
chemotherapy drug melphalan directly to the liver, through the
hepatic artery. The drug is very toxic, but not for normal
cells in the liver.

The system aims to minimize side effects by filtering the
drug out of the blood stream as it leaves the liver, but some
of the drug does leak out.

As a result, the major side effect seen in the trial was
bone marrow suppression.

Delcath has begun a rolling application for its PHP system
at the U.S. Food and Drug Administration and expects to
complete the package later this year.

The company has estimated peak annual U.S. sales of $745
million if the system is approved for use in melanoma patients
whose cancer has spread to the liver. Use in primary liver
cancer as well as metastases from other types of cancer could
put the sales potential at $5.6 billion.


(Reporting by Deena Beasley, editing by Matthew Lewis)

Delcath cancer drug delivery system aids survival